Results 161 to 170 of about 5,569,467 (288)

Investigating transcription factor dynamics in health and disease using FRAP

FEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj, Carolina Vazquez Garzon, Jose Joaquin Velasco, Janine N. Post   +3 more
wiley   +1 more source

High-Dose, Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care? [PDF]

Dermatol Ther (Heidelb)
Torres T, Blauvelt A.
europepmc   +1 more source

Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions

FEBS Letters, EarlyView.
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang, Hyo Been Jin, Chang Min Kim, So Yeon Lee, Hyun Ho Park   +4 more
wiley   +1 more source

Linkage between IL-23 and coronary arterial lesions in pediatric patients with Kawasaki disease. [PDF]

Front Pediatr
Wei Y, Feng S, Wu J, Yang P, Su Y, Yi Q.
europepmc   +1 more source

AscF in the mycobacterial CIII–CIV supercomplex lacks metal and nucleotide binding but links malate oxidation to respiration

FEBS Letters, EarlyView.
The mycobacterial CIII‐CIV respiratory supercomplex is an obligate assembly, encompassing several subunits of unknown functions. We have characterized the intracellular subunit AscF, and show that it is unlikely to be a sensor for metals or nucleotides, but is required for growth on nonfermentable energy sources, and likely works as an adapter for ...
Eni Rile, Riccardo Diamanti, Daniel Lundin, Soni Sharma, Robin Lissner, Coenraad P. Kuil, Martin Högbom, Dirk Bald, Dan Sjöstrand   +8 more
wiley   +1 more source

A sensational IL-23 response [PDF]

Nature Reviews Immunology, 2014
openaire   +1 more source

IL-23 serum levels and IL23R polymorphisms in psoriasis: a meta-analysis of susceptibility and severity. [PDF]

BMC Immunol
Ahmadipanah S, Shariat Rad P, Montaseri M, Nemati H, Sadeghi M, Ramezani M.   +5 more
europepmc   +1 more source

The therapeutic opportunities and pitfalls of using iron ion chelators to treat neurodegenerative diseases

FEBS Letters, EarlyView.
Although too much iron in the brain promotes neurodegeneration, iron ion chelators have had mixed effects in clinical trials. This review explains why; some chelators do not render the iron redox‐inactive (e.g., L1) whereas others do (e.g., desferrioxamine).
Barry Halliwell
wiley   +1 more source

PO:01:010 | Survival of second-line treatment with tnf inhibitors vs il-23 inhibitors after failure of a first tnf inhibitor: a real-life observational study from the italian multicenter birra cohort in patients with psoriatic arthritis

Reumatismo
Background. Since 2021, IL-23 inhibitors (IL-23i) such as guselkumab, and since 2022 risankizumab, have been available for the treatment of psoriatic arthritis (PsA). However, after failure of a first tumor necrosis factor inhibitor (TNFi), switching to
Società Italiana di Reumatologia
doaj  

Mirikizumab: a landmark in IL-23-targeted therapy for ulcerative colitis. [PDF]

Ann Med Surg (Lond)
Iqbal MU, Shafquat E, Khan MO, Abu Nahla U.   +3 more
europepmc   +1 more source